Form 8-K CYTOKINETICS INC For: Aug 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cytokinetics sues Bristol-Myers Squibb over aficamten patent dispute
August 13, 2026 9:26 AM EDTCytokinetics (NASDAQ: CYTK) filed a complaint on August 13, 2026, in the U.S. District Court for the District of Delaware against Bristol-Myers Squibb Company and its subsidiary MyoKardia, Inc., seeking a declaratory judgment related to a patent dispute over its heart drug aficamten.
The... More
